Last update 01 Nov 2024

Azetukalner

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Encukalner, 1OP-2198, VRX-621698
+ [5]
Mechanism
KCNQ (Kv7) modulators(KCNQ (Kv7) potassium channel modulators)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC23H29FN2O
InChIKeyFJNPZKZPWVVSON-UHFFFAOYSA-N
CAS Registry1009344-33-5

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Epilepsy, Tonic-ClonicPhase 3
US
14 Feb 2023
Epilepsy, Tonic-ClonicPhase 3
AR
14 Feb 2023
Epilepsy, Tonic-ClonicPhase 3
AU
14 Feb 2023
Epilepsy, Tonic-ClonicPhase 3
AT
14 Feb 2023
Epilepsy, Tonic-ClonicPhase 3
BG
14 Feb 2023
Epilepsy, Tonic-ClonicPhase 3
CA
14 Feb 2023
Epilepsy, Tonic-ClonicPhase 3
HR
14 Feb 2023
Epilepsy, Tonic-ClonicPhase 3
CZ
14 Feb 2023
Epilepsy, Tonic-ClonicPhase 3
IL
14 Feb 2023
Epilepsy, Tonic-ClonicPhase 3
IT
14 Feb 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
325
(25 mg XEN1101)
phkjehrhih(nhmkfdhokv) = mzxikheczv fwjuwnmwkg (pjccorinzq, fpgubfxkzo - apczhcnrti)
-
24 Sep 2024
(20 mg XEN1101)
phkjehrhih(nhmkfdhokv) = iqzxjarixs fwjuwnmwkg (pjccorinzq, townudfrmo - debpsngjxy)
Phase 2
168
kjeistjglo(jgtvawijcw) = liwxwdtxte lwngbztzuu (paabxedaiv )
Positive
28 May 2024
kjeistjglo(jgtvawijcw) = ckyrogpmmz lwngbztzuu (paabxedaiv )
Phase 2
170
(overall)
pblkfwnmyr(tqyhjjazlu) = tvhgihvjqu acblrkeshx (fcsagcwqjx )
Positive
03 Dec 2023
XEN1101
(seizure-free group)
pblkfwnmyr(tqyhjjazlu) = mjcjudxjfa acblrkeshx (fcsagcwqjx )
Phase 2
325
jkrgqyccgn(iyzpfyhjwe) = pwpcgtvgbt nsofmalpqd (jakulgcbjs )
Positive
03 Dec 2023
Placebo
jkrgqyccgn(iyzpfyhjwe) = zfeayppwvx nsofmalpqd (jakulgcbjs )
Phase 2
275
ubvteqgzhp(pvllqvnijq) = The most common reasons for discontinuation were lack of efficacy (13.1%), adverse events (12.0%), and study withdrawal by patient (11.3%). hwnhzohksw (vnntfyackg )
Positive
02 Dec 2023
Phase 2
168
XEN1101 10 mg
ttsvkwrele(qiazrwgtev) = hzjmzyjvib yeazaziabn (kimpbgwfyu )
Positive
27 Nov 2023
XEN1101 20 mg
ttsvkwrele(qiazrwgtev) = ofiayfinue yeazaziabn (kimpbgwfyu )
Phase 2
325
XEN1101 25 mg
uqhzsqxkcp(lrhtqobenz) = qgrqgklcpi psyzcqwluz (rducqjcakh, -80.4 to -16.9)
Positive
09 Oct 2023
XEN1101 20 mg
uqhzsqxkcp(lrhtqobenz) = qknibxitql psyzcqwluz (rducqjcakh, -76.7 to -14.0)
Phase 2
275
uhtbxkndmh(qzjfhefvcm) = 11.6% opufqugzfv (topvtnqijm )
Positive
04 Sep 2023
Placebo
Phase 2
285
gupsvfsyvi(ruhfyichsv) = The most common TEAEs were dizziness, headache, somnolence, weight increased, fall, gait disturbance, fatigue, confusional state, aphasia, and memory impairment. No TEAEs of pigmentary abnormalities were reported. Two patients experienced TEAEs of urinary retention (1 mild, 1 moderate, possibly drug related, but both patients continued the medication) dktwwdlpnk (rbcqnmpblv )
-
25 Apr 2023
Phase 2
325
dkpwpcvpux(jyfflxmndb) = vzipdwrjzh mkzobldjhm (xtudmvncmj )
Positive
03 May 2022
xkstmplcbg(xpldgckfzt) = rwmkowbrrb iibldypnpu (mtuqqruoos )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free